Pandion Therapeutics Inc

NASDAQ:PAND  
17.27
-0.82 (-4.53%)
Other Pre-Announcement

Pandion Therapeutics Reports Q3 2020 Financial Results

Published: 11/16/2020 22:32 GMT
(PAND) - Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update.
Q3 Loss per Share $0.51.
Q3 Earnings per Share Estimate $-0.44 -- Refinitiv Ibes Data (analyst estimates).
Enrollment and Dosing Complete in Phase 1a Clinical Trial of Pt101; Top-line Results Expected Early 2021.
Pt627 Systemic Pd-1 Agonist Development Candidate Nominated; Ind-enabling Studies Expected to Initiate 4q 2020.